drugset / Trial / NCT05653180
IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
NaSingle-groupOpen-labelTreatment
Summary
This research study is designed to establish whether the combination of IBI310 \& Sintilimab has efficacy in patients with advanced BTC
Timeline
- Start
- 2023-03-10
- Primary completion
- 2023-12-31
- Completion
- 2024-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI310 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |